Thyrotropin Receptor Antibody Levels at Diagnosis and After Thionamide Course Predict Graves' Disease Relapse
Authors:
- 1 August 2016
- journal article
- research article
- Published by SAGE Publications in Thyroid®
- Vol. 26 (8) , 1004-1009
Abstract
Background: Thionamides are associated with a high risk of recurrence following cessation. Thyrotropin receptor-stimulating antibody (TRAb) levels at diagnosis and/or after thionamides may be biomarkers of this risk. This study assesses the natural history of Graves' thyrotoxicosis following thionamide withdrawal and factors that predict recurrence, particularly TRAb levels at diagnosis and cessation. Methods: An observational study was conducted of patients with a first presentation of Graves' disease, who were prescribed (and completed) a course of primary thionamide treatment ( n = 266) in a university teaching hospital endocrine clinic. Recurrence rates over four years and factors predictive of recurrent thyrotoxicosis were assessed. Results: The relapse rate was 31% at one year and 70% at four years. Younger age (39 years [range 30–49 years] vs. 47 years [range 37–53 years]; p = 0.011), higher TRAb levels at diagnosis (8.8 IU/L [range 5.3–17.0 IU/L] vs. 5.7 IU/L [range 4.1–9.1 IU/L]; p = 0.003), and higher TRAb levels at cessation of therapy (1.2 IU/L [range 0–2.3 IU/L] vs. p = 0.003) were associated with a higher risk of relapse. By four years, cessation TRAb 1.5 IU/L ( p = 0.001). TRAb at diagnosis >12 IU/L was associated with an 84% risk of recurrence over four years compared with 57% with TRAbs p = 0.002). Conclusion: High TRAb at diagnosis and/or positive TRAb at cessation of therapy suggest a high likelihood of relapse, mostly within the first two years. They stratify patients likely to need definitive therapy (radioiodine or surgery).Keywords
This publication has 20 references indexed in Scilit:
- Clinical Utility of TSH Receptor AntibodiesThe Journal of Clinical Endocrinology & Metabolism, 2013
- Clinical performance of the Roche cobas e411 automated assay system for thyrotropin-receptor antibodies for the diagnosis of Graves' diseaseAnnals of Clinical Biochemistry: International Journal of Laboratory Medicine, 2011
- Technical evaluation of the first fully automated assay for the detection of TSH receptor autoantibodiesClinica Chimica Acta, 2009
- Long-term follow-up of patients with hyperthyroidism due to Graves’ disease treated with methimazole. Comparison of usual treatment schedule with drug discontinuation vs continuous treatment with low methimazole doses: A retrospective studyJournal of Endocrinological Investigation, 2008
- Prognostic Value of Thyrotropin Receptor Antibodies (TRAb) in Graves' Disease: A 120 Months Prospective StudyEndocrine Journal, 2007
- TSH Receptor Antibody Measurements and Prediction of Remission in Graves' Disease Patients Treated with Minimum Maintenance Doses of Antithyroid DrugsEndocrine Journal, 2006
- Does smoking increase relapse rates in Graves’ disease?Journal of Endocrinological Investigation, 2002
- Age and Gender Predict the Outcome of Treatment for Graves' HyperthyroidismThe Journal of Clinical Endocrinology & Metabolism, 2000
- Clinical Features of Patients with Graves' Disease Undergoing Remission After Antithyroid Drug TreatmentThyroid®, 1997
- Remission Rates with Antithyroid Drug Therapy: Continuing Influence of Iodine Intake?Annals of Internal Medicine, 1987